The

Rodrigo Barbachan Mansur; Elisa Brietzke

doi:10.1590/S2237-60892012000300003

Trend

The "selfish brain" hypothesis for metabolic abnormalities in bipolar disorder and schizophrenia

A hipótese do "cérebro egoísta" para alterações metabólicas no transtorno bipolar e na esquizofrenia

Rodrigo Barbachan Mansur; Elisa Brietzke

http://dx.doi.org/10.1590/S2237-60892012000300003 Trends Psychiatry Psychother, vol.34, n3, p.121-128, 2012

PDF

SciELO

Downloads: 0

Abstract

Metabolic abnormalities are frequent in patients with schizophrenia and bipolar disorder (BD), leading to a high prevalence of diabetes and metabolic syndrome in this population. Moreover, mortality rates among patients are higher than in the general population, especially due to cardiovascular diseases. Several neurobiological systems involved in energy metabolism have been shown to be altered in both illnesses; however, the cause of metabolic abnormalities and how they relate to schizophrenia and BD pathophysiology are still largely unknown. The "selfish brain" theory is a recent paradigm postulating that, in order to maintain its own energy supply stable, the brain modulates energy metabolism in the periphery by regulation of both allocation and intake of nutrients. We hypothesize that the metabolic alterations observed in these disorders are a result of an inefficient regulation of the brain energy supply and its compensatory mechanisms. The selfish brain theory can also expand our understanding of stress adaptation and neuroprogression in schizophrenia and BD, and, overall, can have important clinical implications for both illnesses.

Keywords

Schizophrenia, bipolar disorder, metabolism, brain metabolism, stress, allostasis

Resumo

Alterações metabólicas são frequentes em pacientes com esquizofrenia e transtorno bipolar (TB), levando a uma alta prevalência de diabetes e síndrome metabólica nessa população. Além disso, as taxas de mortalidade entre pacientes são mais altas do que na população geral, especialmente em decorrência de doenças cardiovasculares. Vários sistemas neurobiológicos envolvidos no metabolismo energético têm demonstrado alterações nas duas doenças; no entanto, a causa das alterações metabólicas e a forma como elas se relacionam com a fisiopatologia da esquizofrenia e do TB ainda são arenas em grande parte desconhecidas. A teoria do "cérebro egoísta" é um paradigma recente que postula que, para manter estável seu próprio fornecimento de energia, o cérebro modula o metabolismo da energia na periferia regulando tanto a alocação quanto a ingestão de nutrientes. Apresentamos neste artigo a hipótese de que as alterações metabólicas observadas nesses transtornos são resultado de uma regulação ineficiente do fornecimento de energia do cérebro e seus mecanismos compensatórios. A teoria do cérebro egoísta também pode expandir nosso entendimento sobre a adaptação ao estresse e a neuroprogressão na esquizofrenia e no TB, e, acima de tudo, pode ter implicações clínicas importantes para as duas doenças.

Palavras-chave

Esquizofrenia, transtorno bipolar, metabolismo, metabolismo cerebral, estresse, alostase

References

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.

Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19-28.

Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: data, methods, and results for 2001. Global burden of disease and risk factors. 2006:45-240.

Tohen M, Hennen J, Zarate CM Jr., Baldessarini RJ, Strakowski SM, Stoll AL. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220-8.

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428-36.

Perron BE, Howard MO, Nienhuis JK, Bauer MS, Woodward AT, Kilbourne AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2009;70:1407-15.

Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv.. 2009;60:1059-67.

Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord.. 2002;68:167-81.

Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007;64:1123-31.

Ivleva E, Thaker G, Tamminga CA. Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr Bull.. 2008;34:734-42.

McDonald C, Marshall N, Sham PC, Bullmore ET, Schulze K, Chapple B. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry. 2006;163:478-87.

Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-72.

Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett.. 2006;398:215-9.

Smesny S, Kunstmann C, Kunstmann S, Willhardt I, Lasch J, Yotter RA. Phospholipase A(2) activity in first episode schizophrenia: associations with symptom severity and outcome at week 12. World J Biol Psychiatry. 2011;12:598-607.

Mansur RB, Zugman A, Asevedo E, da Cunha GR, Bressan RA. Cytokines and schizophrenia: possible role of anti-inflammatory medications in clinical and pre-clinical stages. Psychiatry Clin Neurosci.. 2012.

Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33:110-33.

Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun.. 2009;23:1079-82.

Brietzke E, Stabellini R, Grassi-Oliveira R, Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr.. 2011.

McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006;40:616-22.

Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, Andreazza AC. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. Affect Disord.. 2009;114:1-13.

Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol.. 2009;12:441-5.

Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev.. 2011;35:804-17.

Brietzke E, Mansur RB, Soczynska JK, Kapczinski F, Bressan RA, McIntyre RS. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord.. 2012;140:82-91.

Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med.. 2011;41:245-51.

Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23:40-7.

Moreira CL, Brietzke E, Lafer B. Comorbidades médicas em pacientes ambulatoriais com transtorno do humor bipolar tipo 1. Rev Psiquiatr Clin.. 2011;38:227-30.

McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord.. 2010;126:366-87.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. 2011.

Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord.. 2002;26:137-41.

Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-9.

Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord.. 2008;110:149-55.

Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr Bull.. 2012;38:280-4.

Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother.. 2011;11:1017-28.

den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46:1604-10.

Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH. Brain structure and obesity. Hum Brain Mapp. 2010;31:353-64.

Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci.. 2000;23:542-9.

Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab.. 2001;21:1133-45.

Gjedde A. Blood-barrier glucose transfer. Physiology and pharmacology of the blood-brain barrier. 1992:65-115.

Peters A, Schweiger U, Pellerin L, Hubold C, Oltmanns KM, Conrad M. The selfish brain: competition for energy resources. Neurosci Biobehav Rev.. 2004;28:143-80.

Bosy-Westphal A, Kossel E, Goele K, Later W, Hitze B, Settler U. Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure. Am J Clin Nutr.. 2009;90:993-1001.

Hitze B, Hubold C, van Dyken R, Schlichting K, Lehnert H, Entringer S. How the selfish brain organizes its supply and demand. Front Neuroenergetics. 2010;2:7.

Madsen PL, Hasselbalch SG, Hagemann LP, Olsen KS, Bulow J, Holm S. Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow Metab.. 1995;15:485-91.

Schnieder TP, Dwork AJ. Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry. 2011;69:134-9.

Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219-33.

Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry. 2009;14:235-7.

Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, Haile CN. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res.. 2010;44:1236-40.

Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res.. 2007;41:523-9.

Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull.. 2001;55:597-610.

Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol.. 2010;177:575-85.

Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet.. 2005;14:241-53.

Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci.. 2011;29:311-24.

Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci.. 2012;13:293-307.

Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol.. 2009;12:805-22.

Valvassori SS, Rezin GT, Ferreira CL, Moretti M, Goncalves CL, Cardoso MR. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res.. 2010;44:903-9.

Maurer I, Moller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem.. 1997;174:255-9.

Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem.. 1998;71:1002-12.

van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab.. 2008;93:572-7.

Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry. 2007;164:1557-60.

Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry. 2010;15:118-9.

Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord.. 2008;10:607-16.

Oresic M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, Saarni SI. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med.. 2011;3:19.

Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70:997-1000.

Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev.. 2004;44:273-82.

Sublette ME, Bosetti F, DeMar JC, Ma K, Bell JM, Fagin-Jones S. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord.. 2007;9:759-65.

Bentsen H, Solberg DK, Refsum H, Gran JM, Bohmer T, Torjesen PA. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70:97-105.

Ximenes da Silva A, Lavialle F, Gendrot G, Guesnet P, Alessandri JM, Lavialle M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J Neurochem.. 2002;81:1328-37.

Bradley AJ, Dinan TG. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol.. 2010;24(^s4):91-118.

Vieta E, Martinez-De-Osaba MJ, Colom F, Martinez-Aran A, Benabarre , Gasto C. Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med.. 1999;29:971-8.

Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci.. 2001;26:411-6.

Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry. 1995;38:797-802.

Cowansage KK, LeDoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol.. 2010;3:12-29.

Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet.. 2002;71:651-5.

Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res.. 2011;45:995-1004.

Schwartz E, Mobbs CV. Hypothalamic BDNF and obesity: found in translation. Nat Med.. 2012;18:496-7.

Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet.. 2009;17:1050-5.

Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Neurosci.. 2003;6:736-42.

Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci.. 2007;27:14265-74.

Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR. Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med.. 2012;18:564-71.

Chaput JP, Drapeau V, Poirier P, Teasdale N, Tremblay A. Glycemic instability and spontaneous energy intake: association with knowledge-based work. Psychosom Med.. 2008;70:797-804.

Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol.. 1991;260:E67-74.

Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical framework informing research about the role of stress in pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:1-8.

Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract.. 2006;12:269-82.

Moritz S, Burnette P, Sperber S, Kother U, Hagemann-Goebel M, Hartmann M. Elucidating the black box from stress to paranoia. Schizophr Bull.. 2011;37:1311-7.

Shevlin M, Houston JE, Dorahy MJ, Adamson G. Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Schizophr Bull.. 2008;34:193-9.

Horesh N, Iancu I. A comparison of life events in patients with unipolar disorder or bipolar disorder and controls. Compr Psychiatry. 2010;51:157-64.

Horesh N, Apter A, Zalsman G. Timing, quantity and quality of stressful life events in childhood and preceding the first episode of bipolar disorder. J Affect Disord.. 2011;134:434-7.

Thompson KN, Phillips LJ, Komesaroff P, Yuen HP, Wood SJ, Pantelis C. Stress and HPA-axis functioning in young people at ultra high risk for psychosis. J Psychiatr Res.. 2007;41:561-9.

Kim EY, Miklowitz DJ, Biuckians A, Mullen K. Life stress and the course of early-onset bipolar disorder. J Affect Disord.. 2007;99:37-44.

van Winkel R, Stefanis NC, Myin-Germeys I. Psychosocial stress and psychosis: A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull.. 2008;34:1095-105.

Sterling P. Allostasis: a model of predictive regulation. Physiol Behav.. 2012;106:5-15.

Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. Handbook of life stress, cognition and health. 1988:629-49.

Karatsoreos IN, McEwen BS. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci.. 2011;15:576-84.

Berk M, Conus P, Kapczinski F, Andreazza AC, Yucel M, Wood SJ. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust.. 2010;193(^s4):S36-40.

Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev.. 2008;32:675-92.

Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev.. 2009;19:365-84.

Manove E, Levy B. Cognitive impairment in bipolar disorder: an overview. Postgrad Med.. 2010;122:7-16.

Gee DG, Cannon TD. Prediction of conversion to psychosis: review and future directions. Rev Bras Psiquiatr.. 2011;33(^s2):s129-42.

Taylor M, Bressan RA, Pan Neto P, Brietzke E. Early intervention for bipolar disorder: current imperatives, future directions. Rev Bras Psiquiatr.. 2011;33:S213-7.

Marshall M, Rathbone J. Early intervention for psychosis. Schizophr Bull.. 2011;37:1111-4.

McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70:1206-12.